Browse the evidence

GLP-1 receptor agonists show potential therapeutic benefits for psychiatric conditions, including depression, anxiety, binge-eating disorder, and substance use disorders, though evidence quality varies.

GLP-1 agonists may help with depression, anxiety, and binge-eating disorder, in addition to weight loss. However, results for addiction (like alcohol) are mixed. Consult a psychiatrist or physician to see if these medications might support your mental health treatment, especially if you have obesity or diabetes.

Targeting the glucagon receptor (GCGR) with antagonists can promote beta-cell regeneration and improve beta-cell identity in Type 2 Diabetes models.

Research suggests that blocking the glucagon receptor (GCGR) might help regenerate insulin-producing beta cells in people with Type 2 Diabetes. This is a newer area of treatment development, moving beyond just replacing insulin to trying to repair the pancreas itself. While promising in animal studies, this is not yet a standard clinical practice for all patients.

Tirzepatide therapy significantly improves cardiac function (LVEF) and reduces cardiac stress (NT-proBNP) in patients with heart failure over a six-month period.

If you have heart failure and are prescribed tirzepatide, expect measurable improvements in your heart's pumping ability (LVEF) and reduced stress on your heart (NT-proBNP) within six months. This medication also improves your ability to walk and your overall quality of life. Ensure you are monitored by your healthcare provider for dosage adjustments and side effects.

Tirzepatide therapy significantly improves functional capacity (6MWT distance) and quality of life (KCCQ scores) in patients with heart failure.

If you have heart failure and are prescribed tirzepatide, you may experience an increased ability to walk and an overall improvement in your quality of life within six months. This means you might feel less short of breath and more capable of performing daily activities. Discuss these potential benefits with your healthcare provider.

Gastric greater curvature plication combined with Nissen fundoplication (GGCP + Nissen) produces significantly less long-term weight loss and inferior glucose homeostasis compared to sleeve gastrectomy (SG) in patients with obesity and type 2 diabetes models, despite being effective for GERD resolution.

If you have obesity and significant acid reflux, standard sleeve gastrectomy might worsen your reflux. A combined procedure (plication + Nissen) can fix your reflux and provide moderate weight loss, but it is less effective for weight loss and blood sugar control than standard sleeve gastrectomy. Choose based on whether reflux control or maximum weight loss is your primary goal.

Anti-obesity medications (AOMs) are underutilized in China due to limited approved options and physician preference for lifestyle interventions, despite high patient willingness to try new AOMs.

If you are a physician in China, be aware that AOMs are underutilized due to limited options and safety concerns. However, patients are willing to try new AOMs. As new AOMs become available, consider prescribing them for patients who fail lifestyle interventions.

GLP-1 receptor agonists (specifically liraglutide) exert direct anti-inflammatory and chondroprotective effects in osteoarthritis by suppressing NF-κB activation, reducing pro-inflammatory cytokines (IL-1β, IL-6, TNF-α), and downregulating cartilage-degrading enzymes (MMPs, ADAMTS), while promoting type II collagen synthesis.

Research shows that GLP-1 drugs may protect knee cartilage directly by reducing inflammation and stopping enzymes that break down joint tissue, in addition to helping you lose weight. This suggests these drugs might slow the progression of osteoarthritis, not just mask the pain.

GLP-1 receptor agonists reduce the incidence of knee surgeries and slow cartilage loss in patients with knee osteoarthritis and type 2 diabetes, as demonstrated in real-world observational cohorts.

For patients with knee OA and diabetes, using GLP-1 drugs like liraglutide or semaglutide is associated with a lower risk of needing knee surgery and slower loss of knee cartilage compared to not using these drugs. This suggests they may help preserve joint structure over time.

The gut microbiota causally influences obesity and metabolic disorders by modulating the secretion of gut hormones (GLP-1, ghrelin, PYY) and influencing hypothalamic neuroendocrine pathways, suggesting microbiota-based therapies as a potential treatment.

While microbiota-based therapies are still being researched, the gut microbiome plays a role in regulating appetite hormones like GLP-1 and ghrelin. Dietary patterns that support a healthy microbiome may contribute to better metabolic health and weight management.

GLP-1 receptor agonists (specifically Exendin-4, Liraglutide, and native GLP-1) modulate human mesenchymal stem cell (hMSC) function by promoting osteogenesis and inhibiting adipogenesis through context-, dose-, and timing-dependent mechanisms.

GLP-1 medications (like Ozempic or Trulicity) are primarily used for diabetes and weight loss, but research suggests they also interact with your body's stem cells. Specifically, they appear to encourage bone-forming cells to work better while discouraging fat-storing cells from differentiating. This effect depends heavily on the specific drug, the dose, and the timing of exposure. While this is promising for regenerative medicine, it is currently based on lab studies, not human clinical trials for tissue repair.

Ghrelin, the only gastrointestinal hormone that increases appetite, stimulates dopamine release in the VTA to increase food motivation and sex motivation in males, but reduces sex motivation in females during lactation.

Ghrelin increases hunger and food motivation by stimulating dopamine release in the brain. In males, it may also increase sex motivation, while in lactating females, it may reduce sex motivation to prioritize maternal care. Understanding these hormonal signals can help manage hunger and motivated behaviors.

During the stable weight maintenance phase, the appetite-suppressing effects of GLP-1 medications may diminish for some patients, leading to a gradual return of hunger, cravings, and food noise, though often less intense than pre-treatment levels.

If you are on long-term GLP-1 medication and notice your hunger or cravings returning slightly, this is a known phenomenon called the 'stable phase' transition. It does not necessarily mean the drug has failed. You may need to adjust your eating habits or discuss dose adjustments with your doctor. The return of hunger is often less severe than before treatment.

Combination therapy using atomoxetine and oxybutynin reduces OSA severity by approximately 60% by activating pharyngeal dilator muscles.

This combination drug is currently in clinical trials (Phase III) and not yet widely available. It targets the muscle function aspect of sleep apnea. If you are not a candidate for CPAP or weight loss drugs, you may want to ask your doctor about upcoming clinical trials for this specific combination.

Carbonic anhydrase inhibitors such as acetazolamide reduce OSA severity by 40-50% in patients with high loop gain.

If you have high loop gain OSA, ask your doctor about carbonic anhydrase inhibitors like acetazolamide. These can reduce your apnea severity by 40-50% by stabilizing your breathing control. Be aware of potential side effects like tingling or stomach upset.

Brown adipose tissue (BAT) activation and white-to-brown adipose tissue transformation reduce obesity risk by increasing energy expenditure and improving glucose homeostasis.

Focus on strategies that may support metabolic health and energy expenditure, such as exposure to cold or specific dietary patterns, as these may influence brown fat activity. However, consult a healthcare provider for personalized advice, as this is a complex physiological area.

Leptin resistance, caused by impaired blood-brain barrier transport or receptor signaling defects, prevents the hormone from suppressing appetite and regulating body weight in obese individuals.

Understanding leptin resistance highlights why simple calorie counting might fail. It suggests that metabolic health, including blood-brain barrier integrity and receptor sensitivity, is crucial. Work with a healthcare provider to address underlying metabolic health.

GLP-1 receptor agonists (semaglutide and liraglutide) are primarily requested by the public for off-label cosmetic weight loss, often without prescriptions or medical advice, creating a high risk of misuse and safety concerns.

GLP-1 medications like semaglutide and liraglutide are powerful tools for weight management and diabetes, but they are not cosmetic shortcuts. Most requests for these drugs are for weight loss without a prescription, which poses safety risks. If you are considering these medications, consult a healthcare provider to ensure they are appropriate for your health needs and to receive proper guidance on usage and side effects.

GLP-1 receptor agonists and dual incretin therapies (semaglutide, liraglutide, tirzepatide) do not show a disproportional reporting signal for suicidal ideation or suicide attempt compared to non-GLP-1 anti-obesity drugs.

Current pharmacovigilance data does not support a causal link between GLP-1 or dual incretin weight-loss drugs and suicidal ideation or attempts. While patients should be monitored as standard practice, the absolute risk appears neutral compared to other anti-obesity medications.

Non-GLP-1 anti-obesity drugs, specifically naltrexone/bupropion, show elevated disproportional reporting signals for suicidal ideation and suicide attempt compared to GLP-1/dual incretin therapies.

Naltrexone/bupropion shows a higher reporting signal for suicidality compared to GLP-1 drugs, which is consistent with its known pharmacology. Patients using this medication should be monitored for mood changes.

Duodenal Mucosal Resurfacing (DMR) significantly improves glycaemic control in Type 2 Diabetes patients by enhancing insulin sensitivity.

Duodenal Mucosal Resurfacing (DMR) is a new, minimally invasive procedure that can help lower blood sugar in Type 2 Diabetes. It works by treating the duodenum to improve insulin sensitivity. Clinical trials show it reduces HbA1c levels, and the more duodenum treated, the better the result. It is a safe option for those who may not respond well to standard treatments.

Tirzepatide can cause rare, idiosyncratic hepatocellular injury presenting as asymptomatic or symptomatic aminotransferase elevation, which resolves upon drug discontinuation.

If you are taking tirzepatide and develop persistent abdominal pain, nausea, or dark urine, do not assume it is just a standard side effect. Request liver enzyme testing (ALT/AST) immediately. If elevated, stopping the medication typically resolves the injury, but early detection prevents severe liver damage.

Tirzepatide use is associated with a high frequency of early-onset adverse events, with a median time-to-onset of approximately 6.4 days, driven by gastrointestinal disturbances, injection site reactions, and metabolic effects.

If you start tirzepatide, expect side effects like nausea or injection site pain to happen quickly, often within the first week. This is common and usually transient, but you should monitor yourself closely during the initial days of treatment.

Tirzepatide use is associated with specific adverse events in females, including starvation ketoacidosis, menstrual disorders, and postmenopausal hemorrhage.

Women taking tirzepatide should be aware of potential changes in their menstrual cycle, including irregular bleeding or postmenopausal hemorrhage. If you experience these changes, consult your healthcare provider.

Tirzepatide use is associated with specific adverse events in males, including sleep disorders, delayed gastric emptying, and medullary thyroid cancer.

Men taking tirzepatide should be aware of potential sleep issues and digestive delays. Those with a family history of thyroid cancer should discuss the risks with their doctor before starting treatment.